Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway.

Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4421-4. Unique Identifier : AIDSLINE MED/96210659
Fridell RA; Bogerd HP; Cullen BR; Howard Hughes Medical Institute, Duke University Medical Center,; Durham, NC 27710, USA.

Abstract: The Rev protein of HIV-1 is essential for the nuclear export of incompletely spliced viral mRNAs. This action depends on the mutationally defined Rev activation domain, which both binds the nucleoporin-like human cellular cofactor Rab/hRIP and also functions as a nuclear export signal. Protein kinase inhibitor alpha (PKI) also contains a potent nuclear export signal. However, PKI plays no role in nuclear RNA export and instead induces the nuclear export of a specific protein target, the catalytic subunit of cAMP-dependent protein kinase. Here, it is demonstrated that the nuclear export signal of PKI not only binds the Rab/hRIP cofactor specifically but also can effectively substitute for the Rev activation domain in mediating the nuclear export of HIV-1 mRNAs. We conclude that HIV-1 Rev and PKI act through an identical nuclear export pathway and that Rev, rather than using a dedicated RNA export pathway, is instead acting as an adaptor that allows viral mRNAs to access a cellular protein export pathway.

Keywords: Amino Acid Sequence Animal Binding Sites Carrier Proteins/*METABOLISM Cell Nucleus/*METABOLISM Cytomegalovirus/GENETICS Enzyme Inhibitors Gene Products, rev/*METABOLISM Gene Products, rex/*METABOLISM Genetic Vectors Human HIV Core Protein p24/BIOSYNTHESIS HIV-1/*METABOLISM Mammals Molecular Sequence Data Promoter Regions (Genetics) Protein Kinases/*ANTAGONISTS & INHIB Restriction Mapping RNA Splicing RNA, Messenger/*METABOLISM RNA, Viral/*METABOLISM Sequence Homology, Amino Acid JOURNAL ARTICLE
960930
M9690884

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .